United States securities and exchange commission logo





                              June 25, 2020

       Peter Kolchinsky
       Chief Executive Officer
       Therapeutics Acquisition Corp.
       200 Berkeley Street
       18th Floor
       Boston, MA 02116

                                                        Re: Therapeutics
Acquisition Corp.
                                                            Form S-1
                                                            Filed June 15, 2020
                                                            File No. 333-239196

       Dear Mr. Kolchinsky:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Form S-1

       Principal Stockholders, page 114

   1.                                                   We note your response
to comments 5 and 6 of our letter dated June 10, 2020. We note
                                                        that you removed
disclosure stating that your sponsor will have the right to elect the board
                                                        prior to your initial
business combination. However, your disclosure still states: "Holders
                                                        of our public shares
will not have the right to elect any directors to our board of directors
                                                        prior to our initial
business combination." Please advise who will elect your board of
                                                        directors between the
time of this offering and a business combination. In this regard, we
                                                        note disclosure in the
section entitled "Voting rights" on page 19 and on page 120 of your
                                                        filing that you are
required by Delaware law to hold an annual meeting of stockholders to
 Peter Kolchinsky
Therapeutics Acquisition Corp.
June 25, 2020
Page 2

      elect directors and that in any matter submitted to a vote, holders of
the public shares and
      the founder shares (or Class A and Class B shares) will vote together as
a single class.
Redemption of Public Stockholders' Warrants for shares of Class A Common Stock,
page 125

2.    We note your response to comment 8 of our letter dated June 10, 2020.
Please revise your
      disclosure and the heading of this section to clarify that warrant
holders that do not
      exercise their warrants during the redemption period will not receive any
shares, but
      instead will only receive $.10 cash per warrant in the redemption. The
heading and
      disclosure currently suggest that warrant holders would receive shares
upon redemption.
      Similarly, please revise the disclosure in the section "Redemption
procedures and cashless
      exercise" to clarify that it applies to warrant exercises in connection
with the $0.01
      redemption, since both the $0.01 and $0.10 redemptions are for cash.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Jeffrey Lewis at 202-551-6216 or Robert Telewicz at
202-551-3438 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Stacie Gorman at 202-551-3585 or Pam Long at 202-551-3765 with any
other questions.



                                                            Sincerely,
FirstName LastNamePeter Kolchinsky
                                                            Division of
Corporation Finance
Comapany NameTherapeutics Acquisition Corp.
                                                            Office of Real
Estate & Construction
June 25, 2020 Page 2
cc:       Dan Espinoza, Esq.
FirstName LastName